In its 2019 annual IND update to USA FDA, Neovia has reported progress for the continuing phase I(a) dose escalation trial for its lead compound NEV-801. Neovia reported safe dose escalation from 20mg/m2 to 240mg/m2 with no serious adverse events attributable to the investigational drug. Although efficacy is not the prime objective of a dose-escalation phase, 32% disease stabilization and 15% partial response in aggressive, advanced tumors such as ovarian, colon, and pancreatic cancers were also reported. Cohort 7 of the dose-escalation phase is underway in 2020 with a dose of 320mg/m2
Neovia presented preliminary phase I and potential “immunotherapy enhancement” data at the 2018 JP Morgan conference to an international audience of over 1000 attendees.
Neovia presented data from a pilot study using its lead drug candidate NEV-801 showing synergistic effects with PD1 and CTLA4.